There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vaxcyte (PCVX – Research Report) and Apogee Therapeutics, Inc. (APGE – Research Report) with bullish sentiments.
Vaxcyte (PCVX)
In a report issued on May 10, Geoff Meacham from Bank of America Securities maintained a Buy rating on Vaxcyte, with a price target of $101.00. The company’s shares closed last Monday at $65.00.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Vaxcyte is a Strong Buy with an average price target of $102.60, which is a 57.6% upside from current levels. In a report issued on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $106.00 price target.
See the top stocks recommended by analysts >>
Apogee Therapeutics, Inc. (APGE)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Apogee Therapeutics, Inc. today. The company’s shares closed last Monday at $53.81.
According to TipRanks.com, Buren is a 3-star analyst with an average return of
Apogee Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $86.75, which is a 60.4% upside from current levels. In a report issued on May 10, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PCVX:
